Comparative analysis of antitumor activity of CD40L, RANKL, and 4-1BBL in vivo following intratumoral administration of viral vectors of transduced dendritic cells

Journal of Gene Medicine

Volumn 8, Issue 2, 2006, Pages 129-137

  Yurkovetsky, Zoya R ^a   Shurin, Galina V ^a   Barry, Denise A ^b   Schuh, Andre C ^b   Shurin, Michael R ^a   Robbins, Paul D ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

4 1BBL; Cancer gene therapy; CD40L; Dendritic cells; RANKL

Indexed keywords

ADENOVIRUS VECTOR; B7 ANTIGEN; BETA GALACTOSIDASE; CD137 LIGAND; CD40 ANTIGEN; CD40 LIGAND; CD86 ANTIGEN; INTERLEUKIN 12; OSTEOCLAST DIFFERENTIATION FACTOR; TUMOR NECROSIS FACTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GENE THERAPY; CANCER GROWTH; CANCER INHIBITION; CANCER THERAPY; CELL BASED GENE THERAPY; CELL SURVIVAL; COMPARATIVE STUDY; CONTROLLED STUDY; DENDRITIC CELL; DRUG EFFICACY; EXPERIMENTAL NEOPLASM; FEMALE; GENE EXPRESSION; GENE TRANSFER; GENETIC CODE; GENETIC TRANSDUCTION; IMMUNE RESPONSE; IN VIVO STUDY; INOCULATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; RODENT; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; VIRUS RECOMBINANT;

4-1BB LIGAND; ANIMALS; CARRIER PROTEINS; CD40 LIGAND; CELL LINE, TUMOR; CELL SURVIVAL; DENDRITIC CELLS; FEMALE; GENE THERAPY; GENETIC VECTORS; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; NEOPLASMS; RANK LIGAND; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B; TRANSDUCTION, GENETIC; TUMOR NECROSIS FACTORS;

ADENOVIRIDAE; ANIMALIA; MURINAE; RODENTIA;

EID: 32844458812     PISSN: 1099498X     EISSN: None     Source Type: Journal    
DOI: 10.1002/jgm.834     Document Type: Article

References (30)

1. Bett AJ, Haddara W, Prevec L, Graham FL. An efficient and flexible system for construction of adenovirus vectors with insertions or deletions in early regions 1 and 3. Proc Natl Acad Sci U S A 1994; 91: 8802-8806.
2. Cappello P, Novelli F, Forni G, Giovarelli M. Death receptor ligands in tumors. J Immunother 2002; 25: 1-15.
3. Cella M, Scheidegger D, Palmer-Lehmann K, Lane P, Lanzavecchia A, Alber G. Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation. J Exp Med 1996; 184: 747-752.
4. Esche C, Gambotto A, Satoh Y, et al. CD154 inhibits tumor-induced apoptosis in dendritic cells and tumor growth. Eur J Immunol 1999; 29: 2148-2155.
5. Futagawa T, Akiba H, Kodama T, et al. Expression and function of 4-1BB and 4-1BB ligand on murine dendritic cells. Int Immunol 2002; 14: 275-286.
6. Hardy S, Kitamura M, Harris-Stansil T, Dai Y, Phipps ML. Construction of adenovirus vectors through Cre-lox recombination. J Virol 1997; 71: 1842-1849.
7. Hirano A, Longo DL, Taub DD, et al. Inhibition of human breast carcinoma growth by a soluble recombinant human CD40 ligand. Blood 1999; 93: 2999-3007.
8. Josien R, Li HL, Ingulli E, et al. TRANCE, a tumor necrosis factor family member, enhances the longevity and adjuvant properties of dendritic cells in vivo. J Exp Med 2000; 191: 495-502.
9. Josien R, Wong BR, Li HL, Steinman RM, Choi Y. TRANCE, a TNF family member, is differentially expressed on T cell subsets and induces cytokine production in dendritic cells. J Immunol 1999; 162: 2562-2568.
10. Kikuchi T, Crystal RG. Anti-tumor immunity induced by in vivo adenovirus vector-mediated expression of CD40 ligand in tumor cells. Hum Gene Ther 1999; 10: 1375-1387.
11. Kikuchi T, Moore MA, Crystal RG. Dendritic cells modified to express CD40 ligand elicit therapeutic immunity against preexisting murine tumors. Blood 2000; 96: 91-99.
12. Kikuchi T, Worgall S, Singh R, Moore MA, Crystal RG. Dendritic cells genetically modified to express CD40 ligand and pulsed with antigen can initiate antigen-specific humoral immunity independent of CD4+ T cells. Nat Med 2000; 6: 1154-1159.
13. Lu G, Janjic BM, Janjic J, Whiteside TL, Storkus WJ, Vujanovic NL. Innate direct anticancer effector function of human immature dendritic cells. II. Role of TNF, lymphotoxin-alpha(1)beta(2), Fas ligand, and TNF-related apoptosis-inducing ligand. J Immunol 2002; 168: 1831-1839.
14. Ludewig B, Graf D, Gelderblom HR, Becker Y, Kroczek RA, Pauli G. Spontaneous apoptosis of dendritic cells is efficiently inhibited by TRAP (CD40-ligand) and TNF-alpha, but strongly enhanced by interleukin-10. Evr. J. Immunol 1995; 25: 1943-1950.
15. Lum L, Wong BR, Josien R, et al. Evidence for a role of a tumor necrosis factor-alpha (TNF-alpha)-converting enzyme-like protease in shedding of TRANCE, a TNF family member involved in osteoclastogenesis and dendritic cell survival. J Biol Chem 1999; 274: 13 613-13 618.
16. Martinet O, Ermekova V, Qiao JQ, et al. Immunomodulatory gene therapy with interleukin 12 and 4-1BB ligand: long- term remission of liver metastases in a mouse model. J Natl Cancer Inst 2000; 92: 931-936.
17. Melero I, Bach N, Hellstrom KE, Aruffo A, Mittler RS, Chen L. Amplification of tumor immunity by gene transfer of the co-stimulatory 4-1BB ligand: synergy with the CD28 co-stimulatory pathway. Eur J Immunol 1998; 28: 1116-1121.
18. Melero I, Shuford WW, Newby SA, et al. Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors. Nat Med 1997; 3: 682-685.
19. Pirtskhalaishvili G, Shurin GV, Esche C, et al. Cytokine-mediated protection of human dendritic cells from prostate cancer-induced apoptosis is regulated by the Bcl-2 family of proteins. Br J Cancer 2000; 83: 506-513.
20. Shurin GV, Shurin MR, Bykovskaia S, Shogan J, Lotze MT, Barksdale EM Jr. Neuroblastoma-derived gangliosides inhibit dendritic cell generation and function. Cancer Res 2001; 61: 363-369.
21. Shurin GV, Yurkovetsky ZR, Shurin MR. Tumor-induced dendritic cell dysfunction. The Tumor Immunology and Immunotherapy Series, vol. 2, 2003; 112-138.
22. Shurin MR. Dendritic cells presenting tumor antigen. Cancer Immunol Immunother 1996; 43: 158-164.
23. Shurin MR, Lu L, Kalinski P, Stewart-Akers AM, Lotze MT. Th1/Th2 balance in cancer, transplantation and pregnancy. Springer Semin Immunopathol 1999; 21: 339-359.
24. Tada Y, O-Wang J, Yu L, et al. T-cell-dependent antitumor effects produced by CD40 ligand expressed on mouse lung carcinoma cells are linked with the maturation of dendritic cells and secretion of a variety of cytokines. Cancer Gene Ther 2003; 10: 451-456.
25. Tourkova IL, Yurkovetsky ZR, Shurin MR, Shurin GV. Mechanisms of dendritic cell-induced T cell proliferation in the primary MLR assay. Immunoi Lett 2001; 78: 75-82.
26. van Kooten C, Banchereau J. CD40-CD40 ligand. J Leukoc Biol 2000; 67: 2-17.
27. Wong BR, Josien R, Choi Y. TRANCE is a TNF family member that regulates dendritic cell and osteoclast function. J Leukoc Biol 1999; 65: 715-724.
28. Wong BR, Josien R, Lee SY, et al. TRANCE (tumor necrosis factor [TNF]-related activation-induced cytokine), a new TNF family member predominantly expressed in T cells, is a dendritic cell-specific survival factor. J Exp Med 1997; 186: 2075-2080.
29. Yurkovetsky ZR, Robbins PD, Shurin GV, Shurin MR. The TNF superfamily of proteins for cancer therapy. Recent Res. Develop. Cancer 2002; 317-330.
30. Yurkovetsky ZR, Shurin GV, Gambotto A, Kim SH, Shurin MR, Robbins PD. Intratumoral administration of Ad-CD40L or dendritic cells transduced with Ad-CD40L induces antitumor immunity. Cancer Gene Ther 2005; in press.